Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 4.92 subject to Rule 16b-3
| CPIX Stock | USD 4.01 0.49 13.92% |
Slightly above 55% of Cumberland Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Cumberland Pharmaceuticals stock suggests that some investors are interested at this time. Cumberland Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Cumberland Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Cumberland | Build AI portfolio with Cumberland Stock |
Filed transaction by Cumberland Pharmaceuticals Director, 10 Percent Owner, Officer: Chairman And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cumberland Pharmaceuticals Fundamental Analysis
We analyze Cumberland Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cumberland Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cumberland Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Cumberland Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Cumberland Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cumberland Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Cumberland Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cumberland Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Cumberland Pharmaceuticals Related Equities
| BFRI | Biofrontera | 2.00 | ||||
| ORGO | Organogenesis Holdings | 1.52 | ||||
| TKNO | Alpha Teknova | 1.83 | ||||
| LFCR | Lifecore Biomedical | 2.16 | ||||
| ISPC | ISpecimen | 3.97 |
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.